1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,857 | 0,861 | 02.04. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| SYNTHAVERSE Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 51,64 | -0,08 % | Novonesis (Novozymes A/S): Resolutions from the Annual General Meeting 2026 | Today, the Annual General Meeting of Novonesis (Novozymes A/S) was conducted. The following resolutions were made: Approval of the audited Annual Report for 2025Approval of distribution of profit... ► Artikel lesen | |
| GENMAB | 235,30 | -0,25 % | Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons | ||
| ARBUTUS BIOPHARMA | 3,838 | -1,34 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update | Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025 $2.25B Moderna global settlement for infringement of lipid nanoparticle (LNP) delivery... ► Artikel lesen | |
| VERICEL | 27,800 | 0,00 % | Vericel secures $197M BARDA deal, boosting NexoBrid supply plans | ||
| MUSTGROW BIOLOGICS | 0,332 | -8,54 % | Grüne Versprechen, gelbe Lösungen: KWS Saat, Mustgrow Biologics und Corteva im Check | Greenwashing oder echte Innovation? Die Debatte um nachhaltige Investments trifft kaum eine Branche so hart wie die Agrarchemie. Unternehmen wie Corteva, KWS Saat und Mustgrow Biologics arbeiten an... ► Artikel lesen | |
| MOLECULIN BIOTECH | 2,290 | 0,00 % | Moleculin Biotech files to sell 6.37M shares of common stock for holders | ||
| SENSEI BIOTHERAPEUTICS | 31,000 | -0,06 % | Sensei BioTherapeutics GAAP EPS of -$16.72 | ||
| BIOXCEL THERAPEUTICS | 1,040 | +2,16 % | BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting | PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient)... ► Artikel lesen | |
| REGENXBIO | 7,350 | -0,68 % | REGENXBIO Inc.: Regenxbio Reports New Positive Interim Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne
Pivotal dose participants exceeded external controls across... ► Artikel lesen | |
| AKEBIA | 1,204 | +1,01 % | Akebia Therapeutics, Inc.: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors | CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics- , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 8,100 | -0,61 % | Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million | BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare... ► Artikel lesen | |
| FENNEC PHARMACEUTICALS | 5,500 | +0,92 % | Fennec Pharmaceuticals Inc: Fennec grants 377,500 inducement options to new hires | ||
| CORVUS PHARMACEUTICALS | 12,480 | -2,04 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Announced data from cohort 4 of soquelitinib atopic dermatitis Phase 1 trial demonstrating positive safety and efficacy results, including in patients who have received prior systemic therapy Initiated... ► Artikel lesen | |
| CARTESIAN THERAPEUTICS | 5,000 | -2,91 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | ||
| NANOBIOTIX | 26,750 | -2,55 % | Nanobiotix S.A.: NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results | Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck... ► Artikel lesen |
Das Unternehmen SYNTHAVERSE SA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,18 % bei einem Aktienkurs von 0,851 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHAVERSE SA finden Sie auf Wallstreet Online.